Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of the bivalent HPV vaccine (Pichia pastoris) in healthy women aged 18-30 years previously enrolled in study 311-HPV-1003
CTR20230857Phase 4Completed
- Sponsor
- Yuxi Zerun Biotechnology Co., Ltd.
- Start
- Mar 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), sponsored by Yuxi Zerun Biotechnology Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)
Beyond the preview
Go deeper on CTR20230857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230857.